Prof. Matteo Giovanni Della Porta

Home , University of Ferrara, University of Pavia

Curriculum Vitae Replace with First name(s) Surname(s)

PERSONAL INFORMATION

Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University Via Manzoni, 113 - 20089 Rozzano - Milan, Italy Phone +39 02 8224 7668 Fax + 39 02 8224 4592 Mail [email protected] Web mdellaporta.com

Date of birth 29/05/1974 | Nationality Italian

Head, Leukemia Unit - Cancer Center - IRCCS Humanitas Research Hospital Associate professor of Hematology - Humanitas University POSITION Via Manzoni, 113 - 20089 Rozzano - Milan, Italy www.humanitas.it www.hunimed.eu

WORK EXPERIENCE

2016- Head, Leukemia Unit - Cancer Center IRCCS Humanitas Research Hospital Milan, Italy & Associate Professor of Hematology – Humanitas University, Milan Italy

2014-2016 Associate Professor of Clinical Oncology – University of Pavia, Italy

2008-2015 Assistant Professor of Clinical Oncology & Consultant Hematologist, University of Pavia Italy & Department of Hematology IRCCS Policlinico San Matteo, Pavia Italy

EDUCATION AND TRAINING

2003 Board Certification in Hematology - University of Ferrara, Italy

1999 Medical Degree - University of Pavia, Italy

PERSONAL SKILLS Current research interests mainly concern myeloid malignancies (myelodysplastic syndromes, MDS acute myeloid leukemias AML, myeloproliferative neoplasms, MPN)

These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes [Blood. 2006;108(1):337-45 and Leukemia. 2010;24(4):756-64 and J Clin Oncol 2013, J Clin Oncol. 2013 Oct 1;31(28):3557-64], to the identification of the molecular basis of refractory anemia with ringed sideroblasts associated with marked thrombocytosis [Blood. 2009;114(17):3538-45], and to the development of the WPSS [J Clin Oncol. 2007;25(23):3503-10, Blood. 2008;112(3):895-902, Blood. 2014 Apr 10;123(15):2333-42, Leukemia. 2015 Jul;29(7):1502-13] and the CPSS [Blood. 2013;121(15):3005-15] as a valuable tools for risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative disorders, respectively.

In 2008 he joined the European LeukemiaNet working package on myelodysplastic syndromes, aimed at developing the European evidence and consensus-based guidelines

for treatment of myelodysplastic syndromes [Blood. 2013 Oct 24;122(17):2943-64]

In 2010, he joined the International Cancer Genome Consortium Chronic Myeloid Disorders Working Group. This collaboration led to the identification of somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts [N Engl J Med. 2011;365(15):1384-95, Blood. 2011;118(24):6239-46, Blood. 2015 Jul 9;126(2):233-41, Leukemia. 2015 Jan;29(1):66-75].

Mother tongue(s) Italian

Other language(s) UNDERSTANDING SPEAKING WRITING

Listening Reading Spoken interaction Spoken production English C1 C2 C1 C1 C1

ADDITIONAL INFORMATION

Publications Scientific publications include more than 130 peer-reviewed articles in journals covered by the JCR®. Matteo G Della Porta’s H-index is equal to 62 (Google Scholar)

Milano, August 26, 2019